Paxil Injuries

Baum, Hedlund, Aristei & Goldman’s drug department litigates pharmaceutical drug product liability lawsuits.

Baum Hedlund has represented thousands of victims of drug-induced injury and death for more than 30 years. Baum Hedlund has extensive experience in litigating personal injury, wrongful death and consumer class action cases against major drug companies and has been litigating a number of different types of cases against GlaxoSmithKline (GSK), the maker of Paxil, for many years.  Baum Hedlund has the longest track-record of handling SSRI antidepressant litigation.

Antidepressant attorney, Bijan Esfandiari, sets the record straight about "new working paper" on antidepressants and teen suicide and responds to Reason Magazine's recycled and unwarranted conclusions about the rise in teen suicides, declining grades, etc., by pharma-funded academics which have been debunked by other scientists and by the authors themselves.

Baum Hedlund’s Extensive Experience Litigating Paxil Injuries and Death Cases Against GSK

Our law firm filed its first Paxil injury lawsuit against GSK in 2001. In that litigation, Baum Hedlund was appointed lead counsel in charge of the Plaintiffs’ Steering Committee for the Paxil Products Liability Litigation (Multidistrict Litigation MDL-1574) in which Baum Hedlund represented more than 3,000 people across the United States in Paxil injuries cases against GSK.

Paxil Suicide and Suicide Attempt Cases

The firm has been litigating Paxil suicide and suicide attempt cases for over a decade.  As a result of that litigation, Baum Hedlund has collected hundreds of thousands of pages of internal GSK documents and conducted dozens of depositions of GSK executives, employees, physicians, researchers and academics. We have seen the harm antidepressants can cause and the extent to which drug companies will go to protect their enormously profitable drugs and we and our clients have testified about this to the FDA. Baum Hedlund has accumulated a considerable body of evidence demonstrating that Paxil is associated with an increased risk of suicidal behavior in all age groups, not just children and young adults as the current label states.  GSK has been aware of the risk for many years and, although the current label now warns of the risk in children and young adults, it still does not warn the public of the risk in older adults.  In 2004, the FDA asked antidepressant manufacturers to add a black box warning to their labels to alert healthcare providers to an increased risk of suicidality in children and adolescents caused by antidepressants.  In May 2007, the FDA asked antidepressant manufacturers to expand the black box warnings to include young adults, but only up to age 24. Since 2007, the Paxil label has stated the suicidal behavior risk does not extend beyond age 24 even though GSK’s own clinical trials show the risk extends to adults of all ages.  GSK divested responsibility for paroxetine (the generic name for Paxil) in the United States to Apotex, Inc. in January 2014.

StewartDolinBaum Hedlund currently represents the widow of Stewart Dolin, a prominent Chicago attorney who committed suicide after being on paroxetine (generic Paxil) for six days.  Mr. Dolin was 57 at the time of his death.  In her complaint, Mrs. Dolin alleges that GSK’s warning label for Paxil was false and misleading because it affirmatively stated the suicidal behavior risk ends at age 24, but GSK’s own data shows otherwise.  This case is scheduled to go to trial on March 14, 2017.

The Truth About Antidepressant-Induced Suicide

To learn more about the adverse reactions associated with Paxil,
please visit

For more information and resources concerning antidepressants, visit

Paxil Class Action Lawsuits

Baum Hedlund began litigating Private Attorney General consumer fraud class action lawsuits against GSK in 2004 on behalf of individuals and entities (insurance companies, state medical welfare agencies)  in California, Florida, Massachusetts, Nevada, New Jersey, Pennsylvania, Texas and Washington.

The cases were based on internal GSK documents showing that GSK falsely promoted Paxil as an effective medication for children and adolescents despite internal communications acknowledging that Paxil’s pediatric depression clinical trials failed to out-perform sugar pills, yet had higher suicidality rates than sugar pills. Notwithstanding, GSK promoted Paxil as being “remarkably safe and effective” for depressed children. A settlement was reached in April 2007 wherein GSK agreed to reimburse parents for all of the money they paid for their children’s Paxil prescriptions. To learn more about this settlement please visit

Baum Hedlund’s consumer fraud cases on behalf of the entities class (state agencies, insurance companies), settled for $40 million in 2008. This Paxil settlement reimbursed insurance companies for their costs in insuring Paxil purchases paid for by the parents of minors prescribed Paxil or Paxil CR.

Paxil Injuries in the News